What is Dren Bio?
Dren Bio is a California-based biotechnology company dedicated to creating advanced protein engineering technologies designed to deplete disease-causing agents, including cells, protein aggregates, and other harmful substances. The company's primary focus is on developing lead programs targeting hematologic neoplasms and solid cancers. Beyond oncology, Dren Bio is actively exploring applications in auto-immune disorders and diseases characterized by protein aggregation. The company's strength lies in its team of accomplished research and development professionals, who bring extensive collective industry experience to their work.
How much funding has Dren Bio raised?
Dren Bio has raised a total of $65M across 1 funding round:
Series B
$65M
Series B (2022): $65M with participation from Pfizer, Aisling Capital, SR One, 8VC, Revelation Partners, Taiho Ventures, ArrowMark Partners, and HBM Healthcare Investments
Key Investors in Dren Bio
Pfizer
Pfizer is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas, including oncology, internal medicine, and immunology.
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with a focus on biopharmaceutical development.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, providing strategic and operational support.
What's next for Dren Bio?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Dren Bio. This capital infusion is expected to accelerate the advancement of its lead programs in oncology and expand its research into auto-immune disorders and protein aggregation diseases. The backing from prominent investors, including those with a strong focus on healthcare and biotechnology, suggests confidence in Dren Bio's innovative technology and its potential to address significant unmet medical needs. The company is poised to leverage this financial momentum to further its research and development efforts, potentially leading to clinical trials and the eventual commercialization of its therapeutic solutions.
See full Dren Bio company page
